TG4050, the first individualized therapeutic vaccine based on the myvac® platform, is the company's lead asset with demonstrated proof of principle in patients for adjuvant treatment of head and neck cancers. The company has strategic collaborations with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation, positioning itself as a clinical-stage leader in individualized neoantigen therapeutic vaccines.
Cyborg Score Rationale
The company raised €105 million in December 2025 and is funded until early 2028, demonstrating strong capital position. Recent appointments of world-leading cancer immunotherapy experts to the Scientific Advisory Board strengthen scientific leadership. Pipeline momentum with multiple catalysts expected 2026-2027 positions the company well, though clinical-stage risk remains.
Top Insights
Phase I data showed 100% Disease-Free Survival after minimum 2-year follow-up, providing clinical proof of principle for TG4050
Funding runway extended to early 2028 following €105 million capital raise in December 2025
Addition of renowned cancer immunotherapy experts to Scientific Advisory Board strengthens credibility in immune-oncology space
Multiple clinical catalysts expected in 2026-2027 with opportunity to advance toward pivotal Phase 3 trial in head and neck cancer
Named Competitors
mRNA-based neoantigen vaccines — BioNTech personalized oncology program
Immunotherapy programs — Cancer immunotherapy portfolio (collaboration partner)